Description:
Non-alcoholic steatohepatitis (NASH) is a serious liver disease characterized by inflammation and liver cell damage, which can lead to cirrhosis. Despite the absence of approved medications specifically for NASH, there are nearly 80 drug candidates in development. Kalorama Information’s report, NASH Drug Pipeline and Market Overview, provides an in-depth analysis of these drug candidates, including details on developers, drug types, phase studies, and market entry estimates.
Key Features of the Report:
This comprehensive market analysis offers critical data and business planning resources for stakeholders in the NASH treatment market. The report includes:
- Estimated Treatment Costs: Analysis of low-, mid-, and high-range costs for a 30-day supply of NASH therapies.
- NASH Market Estimates by Region: Projections for the United States & Canada, EMEA, Latin America, and Asia Pacific for 2025.
Market Insights:
- NASH Disease Incidence and Prevalence: Detailed statistics and trends.
- NAFLD Incidence and Prevalence: Insights into the broader context of liver diseases.
- Risk Factor Evaluation: Analysis of contributing factors to NASH.
- Pricing Trends: Overview of current and future pricing dynamics.
- Liver Transplant Statistics and Trends: Key data on transplant needs and trends.
- Expected Market Penetration: Projections for the adoption of emerging therapies.
- Global Treatment Options and Emerging Therapies: Review of current and future treatment landscapes.
For further details and to purchase directly, please contact us.
Sample Report: A sample is available as a PDF upon request.
